Clinical Trials on Recurrent Mucosal Melanoma

Total 9507 results

National Cancer Institute (NCI)

Active, not recruiting

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
National Cancer Institute (NCI)

Terminated

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma

United States
Dana-Farber Cancer Institute
AstraZeneca

Withdrawn

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic Melanoma

United States
Fred Hutchinson Cancer Center
Amazon.com Services LLC

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions

United States, Canada
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation; University of Virginia

Completed

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage III Mucosal Melanoma of the Head and Neck | Stage IVA Mucosal Melanoma of the Head and Neck | Stage IVB Mucosal Melanoma of the Head and Neck | Stage IVC Mucosal Melanoma...

United States
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
Hoffmann-La Roche

Completed

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma

Spain, United States, Belgium, Denmark, Canada, Australia
Craig L Slingluff, Jr
University of Virginia

Completed

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (MEL60)

Melanoma | Metastatic Melanoma | Mucosal Melanoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Recurrent Melanoma | Stage IV Melanoma | Uveal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

Canada, United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Withdrawn

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
CHU de Reims

Unknown

Molecular Characterization of Primary Mucosal Melanoma (MELMUQ)

Mucosal Melanoma

France
Viewpoint Molecular Targeting
Mayo Clinic

Completed

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR1)

Melanoma (Skin) | Melanoma Stage IV | Melanoma, Uveal | Melanoma, Mucosal

United States
Yonsei University

Not yet recruiting

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Mucosal Melanoma | Acral Melanoma

Korea, Republic of
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM (SNMM)

Mucosal Melanoma | Sinonasal Melanoma

China
Fudan University
Zhejiang Cancer Hospital; Fujian Cancer Hospital; The Affiliated Nanjing Drum...

Recruiting

Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma (MTAM)

Mucosal Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

Mucosal Melanoma

China
Robert R. McWilliams, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
AnewPharma

Unknown

Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

Mucosal Melanoma

China
Dana-Farber Cancer Institute
Massachusetts General Hospital; Pfizer; Beth Israel Deaconess Medical Center

Completed

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United States
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma

Mucosal Melanoma

China
Memorial Sloan Kettering Cancer Center
Pfizer

Recruiting

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Peking University Cancer Hospital & Institute

Recruiting

Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

Mucosal Melanoma

China
Sun Yat-sen University

Unknown

Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era

Mucosal Melanoma

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Mucosal Melanoma | Neoadjuvant Treatment

China
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
Fudan University

Not yet recruiting

Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Advanced Mucosal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)

Head and Neck Mucosal Melanomas

France
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Washington University School of Medicine

Recruiting

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

Mucosal Melanoma of the Head and Neck

United States
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
University of Michigan Rogel Cancer Center

Recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
University Health Network, Toronto

Recruiting

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe)

Cutaneous Melanoma | Mucosal Melanoma | Melanoma Stage IV

Canada
Mural Oncology, Inc

Recruiting

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6)

Cutaneous Melanoma | Mucosal Melanoma

United States, Australia, Canada, Italy, Korea, Republic of, Spain, Taiwan, United Kingdom
Perspective Therapeutics

Recruiting

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

Metastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, Uveal

United States
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States

Clinical Trials on Recurrent Mucosal Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations